PMID- 37752994
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231020
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment 
      of advanced non-small cell lung cancer with mutated epidermal growth factor 
      receptor: a retrospective study.
PG  - 1248690
LID - 10.3389/fonc.2023.1248690 [doi]
LID - 1248690
AB  - OBJECTIVE: This study mainly observes the efficacy and safety of almonertinib 
      plus chemotherapy compared with almonertinib alone in the second-line treatment 
      of advanced non-small cell lung cancer (NSCLC) with mutated epidermal growth 
      factor receptor (EGFR). METHODS: In this study, clinical data of 68 patients with 
      advanced NSCLC who were treated in Jiangsu Provincial People's Hospital and 
      Nanjing Chest Hospital between April 2020 and December 2022 were collected. Among 
      them, the study group (n=30) received second-line almonertinib combined with 
      platinum-based chemotherapy, while the control group (n=38) received almonertinib 
      alone. The near-term and long-term effects and adverse events of the two groups 
      were compared respectively. RESULTS: The median follow-up time until 31 December 
      2022 was 16.3 months (95% CI: 11.32-21.34). Results of chi-square analysis showed 
      no statistically significant difference in objective response rate (ORR) and 
      disease control rate (DCR) between the study group and the control group (56.73% 
      vs. 55.3%, P>0.05; 100% vs. 86.8%, P>0.05). Log-rank test comparing the two 
      groups revealed that the median progression-free survival (mPFS) of the study 
      group was significantly longer than that of the control group by 3.1 months (12.7 
      vs. 9.6 months, P=0.01). Multivariate COX proportional risk model showed a 
      statistically significant effect of treatment method and PS score on PFS 
      (HR=0.43, P=0.023; HR=3.82, P=0.001). In terms of safety, most of the adverse 
      events (AEs) were mild, with no grade 4-5 in the two groups, and the overall 
      tolerance of patients was good. CONCLUSION: For advanced NSCLC patients with EGFR 
      mutations, second-line treatment with almonertinib plus chemotherapy 
      significantly improved PFS compared with almonertinib alone without a significant 
      increase in adverse events, providing efficacy and safety.
CI  - Copyright (c) 2023 Fang, Xiang and Lu.
FAU - Fang, Xiaoxu
AU  - Fang X
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Xiang, Yan
AU  - Xiang Y
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Lu, Kaihua
AU  - Lu K
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20230911
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10518400
OTO - NOTNLM
OT  - almonertinib
OT  - chemotherapy
OT  - epidermal growth factor receptor mutation
OT  - non-small cell lung cancer
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/09/27 06:42
MHDA- 2023/09/27 06:43
PMCR- 2023/01/01
CRDT- 2023/09/27 03:41
PHST- 2023/06/27 00:00 [received]
PHST- 2023/08/25 00:00 [accepted]
PHST- 2023/09/27 06:43 [medline]
PHST- 2023/09/27 06:42 [pubmed]
PHST- 2023/09/27 03:41 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1248690 [doi]
PST - epublish
SO  - Front Oncol. 2023 Sep 11;13:1248690. doi: 10.3389/fonc.2023.1248690. eCollection 
      2023.